A citation-based method for searching scientific literature

Mathieu Neault, Florence Couteau, Éric Bonneau, Vincent De Guire, Frédérick A Mallette. Int Rev Cell Mol Biol 2017
Times Cited: 9







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Senescence-Associated MicroRNAs.
Rachel Munk, Amaresh C Panda, Ioannis Grammatikakis, Myriam Gorospe, Kotb Abdelmohsen. Int Rev Cell Mol Biol 2017
31
22

Molecular definitions of autophagy and related processes.
Lorenzo Galluzzi, Eric H Baehrecke, Andrea Ballabio, Patricia Boya, José Manuel Bravo-San Pedro, Francesco Cecconi, Augustine M Choi, Charleen T Chu, Patrice Codogno, Maria Isabel Colombo,[...]. EMBO J 2017
878
22

MicroRNAs as Peripheral Biomarkers in Aging and Age-Related Diseases.
S Kumar, M Vijayan, J S Bhatti, P H Reddy. Prog Mol Biol Transl Sci 2017
119
22

The hallmarks of aging.
Carlos López-Otín, Maria A Blasco, Linda Partridge, Manuel Serrano, Guido Kroemer. Cell 2013
22

Senescence-associated beta-galactosidase is lysosomal beta-galactosidase.
Bo Yun Lee, Jung A Han, Jun Sub Im, Amelia Morrone, Kimberly Johung, Edward C Goodwin, Wim J Kleijer, Daniel DiMaio, Eun Seong Hwang. Aging Cell 2006
682
22

Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy.
J C Estrada, Y Torres, A Benguría, A Dopazo, E Roche, L Carrera-Quintanar, R A Pérez, J A Enríquez, R Torres, J C Ramírez,[...]. Cell Death Dis 2013
142
22

Senescence in Human Mesenchymal Stem Cells: Functional Changes and Implications in Stem Cell-Based Therapy.
Valentina Turinetto, Emanuela Vitale, Claudia Giachino. Int J Mol Sci 2016
267
22

Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Yehuda Patt, Cristhiam Rojas-Hernandez, Houman Mohammad Fekrazad, Pranshu Bansal, Fa Chyi Lee. Oncologist 2017
16
11

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
L Fong, Y Hou, A Rivas, C Benike, A Yuen, G A Fisher, M M Davis, E G Engleman. Proc Natl Acad Sci U S A 2001
435
11

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Brian I Rini, Joaquim Bellmunt, Jill Clancy, Kongming Wang, Andreas G Niethammer, Subramanian Hariharan, Bernard Escudier. J Clin Oncol 2014
154
11

Antitumour actions of interferons: implications for cancer therapy.
Belinda S Parker, Jai Rautela, Paul J Hertzog. Nat Rev Cancer 2016
496
11

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.
Courèche-Guillaume Kaderbhai, Corentin Richard, Jean David Fumet, Anne Aarnink, Sandra Ortiz-Cuaran, Maurice Pérol, Pascal Foucher, Bruno Coudert, Laure Favier, Aurélie Lagrange,[...]. Oncoimmunology 2017
8
12

SnapShot: cytokines III.
Cristina M Tato, Daniel J Cua. Cell 2008
13
11

Type I interferons in anticancer immunity.
Laurence Zitvogel, Lorenzo Galluzzi, Oliver Kepp, Mark J Smyth, Guido Kroemer. Nat Rev Immunol 2015
656
11

Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.
Aki Isobe, Kenjiro Sawada, Yasuto Kinose, Chifumi Ohyagi-Hara, Erika Nakatsuka, Hiroshi Makino, Tomonori Ogura, Tomoko Mizuno, Noriko Suzuki, Eiichi Morii,[...]. PLoS One 2015
48
11

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models.
Katherine E Lewis, Mark J Selby, Gregg Masters, Jose Valle, Gennaro Dito, Wendy R Curtis, Richard Garcia, Kathy A Mink, Kimberly S Waggie, Matthew S Holdren,[...]. Oncoimmunology 2017
35
11

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Bernard Escudier, Anna Pluzanska, Piotr Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, Marek Filipek, Bohuslav Melichar, Emilio Bajetta,[...]. Lancet 2007
11

Big opportunities for small molecules in immuno-oncology.
Jerry L Adams, James Smothers, Roopa Srinivasan, Axel Hoos. Nat Rev Drug Discov 2015
245
11

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.
Nobuhiro Tsuchiya, Ako Hosono, Toshiaki Yoshikawa, Kayoko Shoda, Kazuto Nosaka, Manami Shimomura, Junichi Hara, Chika Nitani, Atsushi Manabe, Hiroki Yoshihara,[...]. Oncoimmunology 2017
31
11

Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells.
B Sadlack, J Löhler, H Schorle, G Klebb, H Haber, E Sickel, R J Noelle, I Horak. Eur J Immunol 1995
346
11

Are neutralizing anti-GM-CSF autoantibodies present in all healthy persons?
Anthony Meager, Isabelle Cludts, Robin Thorpe, Meenu Wadhwa. Blood 2010
9
11


Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
Yuan Yuan, Ferdynand J Kos, Ting-Fang He, Hongwei H Yin, Mengsha Li, Nicola Hardwick, Kathryn Zurcher, Daniel Schmolze, Peter Lee, Raju K Pillai,[...]. Oncoimmunology 2017
13
11

Fine-tuning the CAR spacer improves T-cell potency.
Norihiro Watanabe, Pradip Bajgain, Sujita Sukumaran, Salma Ansari, Helen E Heslop, Cliona M Rooney, Malcolm K Brenner, Ann M Leen, Juan F Vera. Oncoimmunology 2016
103
11

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.
Aitziber Buqué, Norma Bloy, Fernando Aranda, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour,[...]. Oncoimmunology 2016
44
11


The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
Rosa Nguyen, Jim Houston, Wing K Chan, David Finkelstein, Michael A Dyer. Cancer Immunol Immunother 2018
19
11

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson, Bernie M Fitzharris, Catriona M McNeil, Andrew G Hill, Antoni Ribas, Michael B Atkins, John A Thompson,[...]. Lancet Oncol 2017
162
11

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.
Claire Vanpouille-Box, Amandine Alard, Molykutty J Aryankalayil, Yasmeen Sarfraz, Julie M Diamond, Robert J Schneider, Giorgio Inghirami, C Norman Coleman, Silvia C Formenti, Sandra Demaria. Nat Commun 2017
860
11

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell, Lorenzo Galluzzi. Oncoimmunology 2017
28
11

New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.
Cavan P Bailey, Tulin Budak-Alpdogan, Christopher T Sauter, Michelle M Panis, Cihangir Buyukgoz, Emily K Jeng, Hing C Wong, Neal Flomenberg, Onder Alpdogan. Oncotarget 2017
12
11

Targeting immunosuppressive adenosine in cancer.
Dipti Vijayan, Arabella Young, Michele W L Teng, Mark J Smyth. Nat Rev Cancer 2017
343
11

Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Lynn E Spitler, Robert W Weber, Robert E Allen, John Meyer, Scott Cruickshank, Edeltraut Garbe, Hui-Yi Lin, Seng-jaw Soong. J Immunother 2009
37
11

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Daniele Generali, Gaynor Bates, Alfredo Berruti, Maria P Brizzi, Leticia Campo, Simone Bonardi, Alessandra Bersiga, Giovanni Allevi, Manuela Milani, Sergio Aguggini,[...]. Clin Cancer Res 2009
108
11

A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
Craig L Slingluff, Sandra Lee, Fengmin Zhao, Kimberly A Chianese-Bullock, Walter C Olson, Lisa H Butterfield, Theresa L Whiteside, Philip D Leming, John M Kirkwood. Clin Cancer Res 2013
73
11

Epigenetic modifiers: basic understanding and clinical development.
Richard L Piekarz, Susan E Bates. Clin Cancer Res 2009
114
11

Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment.
Daniel O Villarreal, Michael J Allegrezza, Melissa A Smith, Diana Chin, Leopoldo L Luistro, Linda A Snyder. Oncotarget 2017
9
11

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.
Valérie Dutoit, Christel Herold-Mende, Norbert Hilf, Oliver Schoor, Philipp Beckhove, Judith Bucher, Katharina Dorsch, Sylvia Flohr, Jens Fritsche, Peter Lewandrowski,[...]. Brain 2012
128
11

Adding STING to the Tale of Oncolytic Virotherapy.
Steve H Thorne. Trends Cancer 2016
4
25

Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies.
Patrik Anderson, Martin Höglund, Stig Rödjer. Am J Hematol 2003
26
11

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.
Howard L Kaufman, Carl E Ruby, Tasha Hughes, Craig L Slingluff. J Immunother Cancer 2014
143
11

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Deborah Charych, Samira Khalili, Vidula Dixit, Peter Kirk, Thomas Chang, John Langowski, Werner Rubas, Stephen K Doberstein, Michael Eldon, Ute Hoch,[...]. PLoS One 2017
87
11

Regulation of antiviral T cell responses by type I interferons.
Josh Crouse, Ulrich Kalinke, Annette Oxenius. Nat Rev Immunol 2015
266
11

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.
Dirk Schadendorf, Paul Nghiem, Shailender Bhatia, Axel Hauschild, Philippe Saiag, Lisa Mahnke, Subramanian Hariharan, Howard L Kaufman. Oncoimmunology 2017
38
11

Mitotic progression following DNA damage enables pattern recognition within micronuclei.
Shane M Harding, Joseph L Benci, Jerome Irianto, Dennis E Discher, Andy J Minn, Roger A Greenberg. Nature 2017
699
11

Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.
Dhifaf Sarhan, Caroline Leijonhufvud, Shannon Murray, Kristina Witt, Christina Seitz, Majken Wallerius, Hanjing Xie, Anders Ullén, Ulrika Harmenberg, Elisabet Lidbrink,[...]. Oncoimmunology 2017
17
11

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Brian I Rini, Susan Halabi, Jonathan E Rosenberg, Walter M Stadler, Daniel A Vaena, San-San Ou, Laura Archer, James N Atkins, Joel Picus, Piotr Czaykowski,[...]. J Clin Oncol 2008
706
11

New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators.
Amy L Wilson, Magdalena Plebanski, Andrew N Stephens. Curr Med Chem 2018
13
11


CARs on a highway with roadblocks.
Lorenzo Galluzzi, Peter Martin. Oncoimmunology 2017
4
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.